SequelSEC

Roivant Sciences Ltd. ROIV

Pharmaceutical Preparations · CIK 0001635088 · Fiscal year ends 0331

Revenue
$7.53M
Fiscal year ended 2026-06-30
Operating income
-$596.14M
Fiscal year ended 2026-06-30
Free cash flow
-$821.06M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$9.80BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-09-30
Float per share$13.62Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1186.4×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-09-30, not today, and each multiple below it uses the figures for the fiscal year ending 2026-03-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue4190.9%95th
CapEx / revenue99.4%94th
Current ratio18.37x94th
FCF margin-9183.5%8th
R&D / revenue8254.4%92th
Operating margin-6235.7%13th
Revenue YoY growth-71.6%17th
Net margin-3629.2%19th

Roivant Sciences Ltd. (ROIV) reported revenue of $7.53M and net income of -$266.25M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Roivant Sciences Ltd.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Roivant Sciences Ltd. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$7.53M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$596.14M
Net income-$266.25M
Research & development$730.91M
Weighted-average diluted sharesUnavailable
Pretax income-$289.88M
Income tax expense$124.72M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$641.97M
Selling & marketingUnavailable

Balance

Roivant Sciences Ltd. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$1.25B
Total assets$5.31B
Current assets$4.74B
Total liabilities$384.62M
Current liabilities$283.60M
Total equity incl. NCI$4.92B
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$25.08M

Cash flow

Roivant Sciences Ltd. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$816.47M
Capital expenditures$4.59M
Investing cash flow$684.64M
Financing cash flow$140.49M
Net change in cash$11.93M
Stock-based compensation$347.33M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.85M

Derived

Roivant Sciences Ltd. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$821.06M
Gross marginUnavailable
Operating margin-7914.8%
FCF margin-10901.0%
SBC / revenue4611.4%
Current ratio16.72x
Revenue YoY growth-67.6%
Net margin-3535.0%
R&D / revenue9704.0%
CapEx / revenue61.0%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ROIV in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-K · Filed 2026-05-20View SEC filing
10-Q · Filed 2026-02-06View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-K · Filed 2025-05-29View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.